Inferra AI / Company / TXG
10X Genomics, Inc.
TXG · Industrials
Last earnings Aug 6, 2026
Key results
Recent Updates revenuequarter
$172.9 million
Recent Updates Revenue was $172.9 million for the second quarter.
SEC original ↗10X Genomics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Revenuequarter
$145.6 million
Excluding $27.3 million related to a patent litigation settlement, revenue was $145.6 million.
SEC original ↗10X Genomics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Second Quarter 2025 Financial Results Revenue was $172.9 million for the second quarter of 2025.
SEC original ↗10X Genomics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Excluding $27.3 million related to a patent litigation settlement, revenue was $145.6 million, a 5% decrease from the corresponding period of 2024, primarily driven by a decrease in instrument revenue.
SEC original ↗10X Genomics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Gross marginquarter
72%
Gross margin was 72% for the second quarter of 2025, as compared to 68% for the corresponding prior year period.
SEC original ↗10X Genomics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Excluding the impact of license and royalty revenue, gross margin was 67% for the second quarter of 2025.
SEC original ↗10X Genomics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Operating incomequarter
$30.1 million
Operating income was $30.1 million for the second quarter of 2025, as compared to operating loss of $41.7 million for the corresponding prior year period.
SEC original ↗10X Genomics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Net incomequarter
$34.5 million
Net income was $34.5 million for the second quarter of 2025, as compared to a net loss of $37.9 million for the corresponding prior year period.
SEC original ↗10X Genomics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
AI analysis
Q2 2025 · reported Aug 7, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
GAAP gross margin
Percent of revenue, as stated
EX-99 · Aug 7, 2025 Margin values as stated in the release.
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Recent Updates revenue | $172.9 million | — | — |
| Revenue | $145.6 million | — | — |
| Gross margin | 72% | — | 68% |
| Operating income | $30.1 million | — | — |
| Net income | $34.5 million | — | — |
Guidance · company-stated
Direction: raised
No guidance located in the held release
“2026 Financial Guidance 10x Genomics is raising its full year 2026 revenue guidance and now expects revenue in the range of $610 million to $630 million, versus the previous range of $600 million to $625 million.”
Margin
Capital allocation
, results of operations, financial position, sufficiency of our capital resources, business outlook, future events, business conditions, key business metrics and key factors affecting our performance, revenues, gross margin, expenses, organization, business and other trends, expected future investments including anticipated capital expenditures, anticipated size of market opportunities and our ability to capture them, expected uses, plans and expectations regarding entering the clinical and diagnostic markets, the timing and outcome of regulatory filings and approvals, performance and benefits of our products and services, business trends and other information.
Event summary
10x Genomics Reports Second Quarter 2025 Financial Results
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
, results of operations, financial position, sufficiency of our capital resources, business outlook, future events, business conditions, key business metrics and key factors affecting our performance, revenues, gross margin, expenses, organization, business and other trends, expected future investments including anticipated capital expenditures, anticipated size of market opportunities and our ability to capture them, expected uses, plans and expectations regarding entering the clinical and diagnostic markets, the timing and outcome of regulatory filings and approvals, performance and benefits of our products and services, business trends and other information.
SEC original ↗10X Genomics, Inc. — 10-Q Quarterly report10-QAug 7, 2026
The available-for-sale debt securities are subject to a periodic impairment review.
SEC original ↗10X Genomics, Inc. — 10-Q Quarterly report10-QAug 7, 2026
The Company estimated the weighted-average grant date fair values of shares granted under the TSR component of the 2026 PSUs using a Monte Carlo simulation model with the following assumptions: Expected volatility 64 % Risk-free interest rate 3.4 % Expected dividend yield % In March 2025, the Company granted 561,603 PSUs ( 2025 PSUs ) under the 2019 Plan to certain members of management, which are subject to the achievement of certain market-condition and performance-condition goals established by the Company s Compensation Committee of the Board of Directors.
SEC original ↗10X Genomics, Inc. — 10-Q Quarterly report10-QAug 7, 2026
The holders of our Class A and Class B common stock (together, "common stock") have identical liquidation and dividend rights but different voting rights.
SEC original ↗10X Genomics, Inc. — 10-Q Quarterly report10-QAug 7, 2026
Strategy & priorities
Announced a partnership with the Genome Institute of Singapore on the TISHUMAP initiative, which will leverage Xenium and AI to uncover novel biomarkers and therapeutic targets for cancer and inflammatory diseases.
SEC original ↗10X Genomics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
We re focused on disciplined execution, and remain confident in the strength of our technology, the momentum behind our platforms and the significant long-term opportunity in front of us.
SEC original ↗10X Genomics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
s expectations regarding our plans, objectives, goals, beliefs, business strategies, acquisitions of Scale Biosciences, Inc.
SEC original ↗10X Genomics, Inc. — 10-Q Quarterly report10-QAug 7, 2026
(the Company ) is a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biology.
SEC original ↗10X Genomics, Inc. — 10-Q Quarterly report10-QAug 7, 2026
Overview We are a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biology.
SEC original ↗10X Genomics, Inc. — 10-Q Quarterly report10-QAug 7, 2026
Risks & headwinds
Excluding $27.3 million related to a patent litigation settlement, revenue was $145.6 million.
SEC original ↗10X Genomics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Amid continued uncertainty in the funding environment, we re encouraged by the resilience of our business and the dedication of our team.
SEC original ↗10X Genomics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Excluding $27.3 million related to a patent litigation settlement, revenue was $145.6 million, a 5% decrease from the corresponding period of 2024, primarily driven by a decrease in instrument revenue.
SEC original ↗10X Genomics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
This figure also reflects approximately $4.0 million of revenue that resulted from customers in China accelerating purchases from the third quarter into the second quarter in anticipation of potential tariff changes.
SEC original ↗10X Genomics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
The decrease was primarily driven by a $40.7 million gain on settlement related to the litigation settlement.
SEC original ↗10X Genomics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
This guidance reflects approximately $4.0 million of revenue that resulted from customers in China accelerating purchases from the third quarter into the second quarter in anticipation of potential tariff changes.
SEC original ↗10X Genomics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
33 documents- Q2 2026
- 10-QTXG
Aug 7, 2026
- 8-KTXG
Aug 6, 2026
- Q1 2026
- 8-KTXG
Jun 8, 2026
- 10-QTXG
May 8, 2026
- 8-KTXG
May 7, 2026
- Q4 2025
- 10-KTXG
Feb 13, 2026
- 8-KTXG
Feb 12, 2026
- 8-KTXG
Jan 12, 2026
- Q3 2025
- 8-KTXG
Nov 14, 2025
- 10-QTXG
Nov 7, 2025
- 8-KTXG
Nov 6, 2025
- Q2 2025
- 10-QTXG
Aug 8, 2025
- 8-KTXG
Aug 7, 2025
- Q1 2025
- 8-KTXG
Jun 5, 2025
- 8-KTXG
May 14, 2025
- 10-QTXG
May 9, 2025
- 8-KTXG
May 8, 2025
- Q4 2024
- 10-KTXG
Feb 13, 2025
- 8-KTXG
Feb 12, 2025
- 8-KTXG
Jan 13, 2025
- EX-99TXG
Jan 13, 2025
- Q3 2024
- 10-QTXG
Oct 29, 2024
- 8-KTXG
Oct 29, 2024
- 8-KTXG
Oct 9, 2024
- EX-99TXG
Oct 9, 2024
- Q2 2024
- 10-QTXG
Aug 8, 2024
- 8-KTXG
Aug 8, 2024
- EX-99TXG
Aug 8, 2024
- 8-KTXG
Jul 11, 2024
- Q1 2024
- 8-KTXG
Jun 20, 2024
- 8-KTXG
Jun 13, 2024
- 10-QTXG
Apr 30, 2024
- 8-KTXG
Apr 30, 2024
Earnings releases
11 documentsPresentations
0 documentsNo presentations for 10X Genomics, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for 10X Genomics, Inc. are held in this edition of the library.
Mentioned by
1 companyOther tracked companies whose held documents mention 10X Genomics, Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.
“vides Outlook for 2026 PLEASANTON, Calif. February 12, 2026 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single… …$642.8 million for the full year of 2025. Excluding $44.1 million of non-recurring revenue related to patent litigation settlements, ”
See also the earnings calendar for every tracked company’s next earnings date.